<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444235</url>
  </required_header>
  <id_info>
    <org_study_id>CL-N-CSM-III/01/08</org_study_id>
    <nct_id>NCT01444235</nct_id>
  </id_info>
  <brief_title>Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery</brief_title>
  <official_title>A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N Versus Custodiol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. F. Köhler Chemie GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. F. Köhler Chemie GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the cardioprotective effects and safety of two cardioplegic solutions&#xD;
      (solutions used during a cardiac arrest in the heart surgery) in patients undergoing&#xD;
      cardiopulmonary bypass for coronary artery bypass surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this investigation is to compare the cardioprotective effects and safety of&#xD;
      two cardioplegic solutions, HTK Cardioplegic Solution (Custodiol) and Custodiol-N in patients&#xD;
      undergoing cardiopulmonary bypass for coronary artery bypass surgery. The study design is a&#xD;
      prospective, double blind, multicenter, randomized, Phase III comparison study intended to&#xD;
      demonstrate non-inferiority in surgical outcome between Custodiol and Custodiol-N as&#xD;
      determined by CK-MB area under the curve (primary endpoint), catecholamine&#xD;
      requirement(cumulative dose) and cardiac Troponin T, occurrence of comorbid events&#xD;
      postoperatively (e.g., myocardial infarction).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CK-MB area under the curve within 24 hours</measure>
    <time_frame>Up to 24 hours after the aortic clamp release</time_frame>
    <description>Measurements will be carried out at the following timepoints: 4,8,12,16,20,24 hours (± 30 min) after release of the aortic cross clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catecholamine requirement</measure>
    <time_frame>24 hours (cumulative dose)</time_frame>
    <description>Catecholamine requirement on surgical ICU within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CK-MB peak</measure>
    <time_frame>Up to day 5</time_frame>
    <description>CK-MB peak on the days 2, 3, 4 and 5 after removal of aortic cross clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality any time during post-op through Day 30</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>Mortality will be documented at any time during post-op through Day 30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <arm_group>
    <arm_group_label>Custodiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Custodiol-N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Custodiol-N</intervention_name>
    <description>Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes</description>
    <arm_group_label>Custodiol-N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Custodiol</intervention_name>
    <description>Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused</description>
    <arm_group_label>Custodiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The study population will be selected from patients of either sex with coronary artery&#xD;
        disease (CAD) who are to undergo cardiopulmonary bypass for coronary artery bypass surgery.&#xD;
&#xD;
          1. Patients &gt;/=35 and &lt;/=80 years of age&#xD;
&#xD;
          2. Male or female with 2 or 3 vessel coronary disease, who are scheduled for elective CBP&#xD;
             surgery for coronary revascularisation&#xD;
&#xD;
          3. Presence of definite CAD for which surgical intervention is deemed necessary, without&#xD;
             evidence of ongoing infarction.&#xD;
&#xD;
             Patients with unstable angina can be included as long as there is no objective&#xD;
             (negative cardiac isoenzymes in the immediate six hours preceding CABG, current&#xD;
             intravenous use of nitrate therapy) or subjective (absence of prolonged symptoms&#xD;
             suggestive of coronary insufficiency that do not respond to pharmacologic&#xD;
             intervention) evidence of myocardial necrosis.&#xD;
&#xD;
          4. Eligibility for Swan-Ganz-Catheter&#xD;
&#xD;
          5. Able to understand character and individual consequences of the clinical trial and to&#xD;
             provide written informed consent to participate in the study&#xD;
&#xD;
          6. No evidence of severe organic or psychiatric disease by history or physical&#xD;
             examination&#xD;
&#xD;
          7. No history of alcohol abuse, illicit drug use, significant mental illness, physical&#xD;
             dependence to any opioid, or no any history of drug abuse or addiction within 12&#xD;
             months of study enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing valve repair or replacement&#xD;
&#xD;
          2. History of recent (&lt; 6 weeks) Q-wave myocardial infarction&#xD;
&#xD;
          3. Left ventricular ejection fraction &lt; 35% (as assessed by any one of the following:&#xD;
             contrast ventriculography, multigated acquisition scanning [MUGA], or 2-D ECHO)&#xD;
&#xD;
          4. Patients on intra-aortic balloon devices or with history of previous coronary artery&#xD;
             bypass surgery&#xD;
&#xD;
          5. Pregnant or lactating patients&#xD;
&#xD;
          6. Patients who have participated in any other investigational studies within 30 days&#xD;
             previous to enrollment&#xD;
&#xD;
          7. Patients in cardiogenic shock (defined as a systolic BP &lt; 90 mmHg for over one hour&#xD;
             despite inotropic and chronotropic support)&#xD;
&#xD;
          8. Patients with severe chronic obstructive lung disease (FEV1 &lt; 50%)&#xD;
&#xD;
          9. Previous cardiac valvular disease (clinical relevant)&#xD;
&#xD;
         10. Dialysis or creatinine &gt; 2 mmol/L&#xD;
&#xD;
         11. BMS-Stent &lt; 4 weeks&#xD;
&#xD;
         12. DES-Stent &lt; 6 month&#xD;
&#xD;
         13. Guidance depended Plavix therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabor Szabo, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiac Surgery of University of Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolaus Pizanis, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Thorax- und Kardiovaskuläre Chirurgie, Universitätsklinikum Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florian Wagner, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Herz- und Gefäßchirurgie, Universitäts-Krankenhaus Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thorsten Doenst, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Jena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Misfeld, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Leipzig GmbH, Klinik für Herzchirurgie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Thorax- und Kardiovaskuläre Chirurgie, Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abt. Herzchirugie, Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2011</study_first_posted>
  <last_update_submitted>May 16, 2013</last_update_submitted>
  <last_update_submitted_qc>May 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAD, ACVB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

